Stroke trial hit its interim milestone as cash runs into late 2027.
Why Is DiaMedica Therapeutics Inc. (DMAC) Stock Down Today?
Updated Nov 16, 2026 8:00 PM ET · Prev Close $8.79
Primary Move Catalyst & Conviction
65% Signal ConvictionPharmaceuticals & Therapeutics sector moving together
This appears to be a sector-wide move. The Pharmaceuticals & Therapeutics sector is down 3.6% on average.
Market & Sector Relative Strength
DMAC lagging the S&P 500 by -2.38%Options Flow & Execution Desk
Bullish Flow · P/C 0.05Recent DMAC Catalyst Headlines
Verified WireDiaMedica Therapeutics Nasdaq Dmac expects a key interim analysis of its acute ischemic stroke trial in the first quarter of 2027, after reaching the required enrollment threshold in October, executives said on the compa
Moby summary of DiaMedica Therapeutics Inc.'s Q3 2026 earnings call
Minneapolis, November 12, 2026--DiaMedica Therapeutics Inc. DiaMedica or the Company Nasdaq DMAC , a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia PE , fetal growth rest
1–3 Day Expected Range & Key Level
45% Follow-ThroughWatch for breakdown below $8.41
Technical Regime (DMAC)
MIXED MA TREND1-Year Historical Move Analogs
43 EventsSessions in the past year where DMAC moved >3.0% down:
Retail & Crowd Sentiment
NeutralSCAG announced a strategic cooperation agreement with China Huaye Group. The agreement is bullish for SCAG as it expands their reach into the Chinese market.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a reco...
Get Instant DMAC Catalyst Alerts
Receive an email alert when DMAC triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversDMAC Session & Catalyst FAQ
Why is DMAC stock down today?
This appears to be a sector-wide move. The Pharmaceuticals & Therapeutics sector is down 3.6% on average.
Is DMAC stock a buy or sell right now?
Today's session carries a 65% catalyst conviction score on 0.59x relative volume (low participation). Our multi-factor model currently rates DMAC as HOLD. Review full valuation, quality, and timing signals on the DMAC Buy or Sell Decision Brief →
What is DMAC's intrinsic value and expected trading range?
At $8.41, DMAC's modeled 1-to-3 session range is $8.16 – $8.58, with a key inflection level at $7.99 (support). Compare current price against multi-year cash flow projections in the DMAC Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for DMAC?
RSI at 46.0 reflects soft below-midline momentum. DMAC trades at $8.41 relative to its 20-day SMA ($9.24) and 50-day SMA ($8.24), reflecting a mixed moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.